Purpose Cytomegalovirus retinitis (CMVR) has been the most common cause of visual loss in AIDS patients. We investigate whether the pattern of disease has changed since the introduction of triple therapy.
treatment, the rate of relapse and inexorable progression increases with each subsequent attack, with the development of viral resistance and the decline of the patient's immune function.
With the advent of triple therapy (using a combination of two reverse transcriptase inhibitors and one protease inhibitor), some patients have had their HIV-RNA viral load significantly reduced and CD4 counts boosted to over 100 cells/mm3. This partial restitution of immune function appears to have resulted in a clear benefit in patient survival and a decrease in the number of opportunistic infections. 3 This study reports on our experience of the ocular manifestations of AIDS over a 2 year period in one HIV unit (total patient population at the conclusion of the study of 480, with more than 180 patients currently on triple therapy) from January 1996 to December 1997. Triple therapy was introduced in October 1996.
Patients and methods
All the records of patients with AIDS-related CMVR seen at St Bartholomew's Hospital between January 1996 and December 1997 were reviewed. Data collected included date of diagnosis of AIDS and CMVR; dates, number and extent of reactivations; details of systemic and intravitreal anti-CMV therapy; best corrected Snellen visual acuity; and ocular features including cataract, uveitis, maculopathy and retinal detachment. The extent of CMVR was assessed from fundal photographs and classified according to a standard protocol. 2 Concurrent. opportunistic infections, timing and details of anti-retroviral treatment, CD4 counts and viral load were also noted.
From October 1996 triple therapy consisting of one protease inhibitor and two nucleoside analogues was commenced in patients with a low or decreasing CD4 count «350 cells/mm3), a high or rising viral load (>10 000 copies/ml), new opportunistic infections, or according to patient desire to start the treatrtlent regimen. CD4 count and viral load were monitored 3 monthly and therapeutic success was judged by a rising CD4 count and a decreasing viral load «400 copies/ mm3).
Results
Twenty-four patients (38 eyes) with CMVR were seen in the HIV eye clinic between January 1996 and December 1997. We analysed all our results with regard to the use of triple therapy, resulting in two cohorts of patients: the non-TT cohort consisting of 15 patients (23 eyes) who never received triple therapy or who were on triple therapy for less than 3 months before death; and the TT cohort of 9 patients (15 eyes) who received triple therapy for more than 3 months. The latter group was also analysed with regard to rates of relapse during the periods before and after triple therapy. There were 7 survivors (11 eyes) at the conclusion of the study.
There were 23 men and 1 woman. The median age at presentation was 36.5 years (range 29-45 years). Of these patients 19 were male homosexuals, 1 woman and 1 man were heterosexual, 2 were from endemic areas in Africa, and 1 received contaminated blood products in Africa. The median follow-up time was 323 days (range 30-901 days).
The prevalence of CMVR was 33 eyes (19 patients) in the 12 month period between January 1996 and December 1996 and 12 eyes (7 patients) between January 1997 and December 1997, respectively. The incidence of new CMVR was 21 eyes (15 patients) in the first 12 month period and 4 eyes (4 patients) in the second 12 month period. There were no new cases seen in patients who had been on triple therapy for more than 3 months.
Ten patients (41.6%) had extraocular CMV preceding the diagnosis and had undergone previous treatment with ganciclovir. This included oesophagitis, gastritis, duodenitis, colitis, cholangitis and encephalitis.
Initial findings
Four of twenty-four (16.6%) patients had bilateral disease at first presentation. An additional 10 patients developed CMVR in the contralateral eye during follow-up, making a total of 14 (58.3%) patients with bilateral ocular involvement. No patient developed new bilateral disease after commencing triple therapy. The median visual acuity (VA) at presentation was 6/9 (range 6/5 to hand movements), with 2 patients presenting with retinal detachment at first visit. Five eyes had zone 1 disease at presentation. At initial diagnosis, 10 (41.6%) patients were asymptomatic, with 7 complaining of floaters and photopsia, 3 of scotomas and 4 of visual loss.
Survival and concurrent diseases
During the course of follow-up, 16 patients (66.7%) died: 15 from AIDS-related diseases and 1 from suicide. One patient was lost to follow-up after 1 month. The latter 2 patients were excluded from the survival analysis. Median survival after CMVR diagnosis in the dead cohort was 376 days (range 77-901 days) compared with the cohort of 7 survivors who have survived a median of 598 days from CMVR diagnosis (range 110-731 days) at the last follow-up visit. Two of the seven survivors were already being treated with triple therapy at the time of CMVR diagnosis, and the remaining 5 were changed onto triple therapy. There were 15 deaths (1 from suicide) in the non-TT (100%) cohort and 2 deaths in the TT cohort. The median time on triple therapy in the TT group was 12 (range 5-15) months.
All patients had concurrent AIDS-associated disease. Twelve patients had Pneumocystis carinii pneumonia, 16 had oral candidiasis, 9 had mycobacterial infections, 8 had Kaposi's sarcoma, 3 had high-grade non-Hodgkin's lymphoma and 10 had extraocular CMV preceding the diagnosis of CMVR.
CMVR reactivations
The median time to relapse in all patients was 69 days. The median time to first relapse was 130 days. The median time to relapse in the non-TT group was 47 days, and 85.5 days in the TT group. In the TT group the median time to reactivation before triple therapy was 79 days and 179 days following triple therapy. The median period of inactivity from last reactivation to last follow up visit/death in the TT group was 202 days.
Treatment
The treatment of CMVR was according to a standard regiPlen? Patients were induced with either intravenous ganciclovir or foscarnet or a combination of both and maintained on one drug only. Since early 1997 intravenous cidofovir has been used in resistant cases or in patients who were unable to tolerate foscarnet or ganciclovir. Most patients required changes of treatment due to development of viral resistance during the course of the disease. Six patients received cidofovir. Eight patients received oral ganciclovir maintenance. Seven patients received intravitreal injections of ganciclovir (2 mg/O.1 ml) with a median of 2 per eye (range 1-10). One patient had an insertion of a ganciclovir sustained release device. No patient developed ocular hypotony. None had received intravitreal cidofovir.
Visual loss
During the study period 2 patients (2 eyes) presented with a visual acuity of < 6/18 in the affected eye and 13 patients (19 eyes) went on to develop significant visual loss (defined as the loss of 2 or more lines of best corrected Snellen acuity). The causes of visual loss according to triple therapy status were as follows: Before triple therapy 10 p atients (12 eyes) had significant visual loss from a combination of retinal detachment, zone 1 disease and maculopathy. After triple therapy, 3 patients (5 eyes) had significant visual loss from cataracts and maculopathy. Nineteen (79%) patients in the total cohort had an acuity of 6/12 or better in the better eye. In the non-TT cohort no patient had a visual acuity of 6/60 or worse in the better eye at death. At last follow-up in the TT cohort, 2 of the 7 surviving patients had a visual acuity of 6/60 or worse in the better eye. One of the survivors became legally blind before commencing triple therapy.
Ocular features
Nine of the 14 patients (64%) with bilateral disease had zone 1 involvement. Of these, 6 had bilateral zone 1 involvement. Only 2 of the 10 patients (20%) with unilateral disease had zone 1 involvement. There was no new zone 1 disease after triple therapy.
Before triple therapy, 6 patients (7 eyes) developed retinal detachment. There was one case of retinal detachment after triple therapy. Before triple therapy there were 3 patients (3 eyes) with maculopathy, and 6 patients (10 eyes) developed maculopathies after triple therapy. In 4 patients with bilateral maculopathies there was associated uveitis. None of these patients had received rifabutin. The time course of the development of uveitis after initiation of triple therapy in the 4 patients with anterior uveitis and vitritis was 2, 3, 6 and 11 months.
Use of cidofovir
The introduction of cidofovir into the treatment regimen also complicates the clinical picture.4-6 Of the 7 patients who received intravenous cidofovir, one developed bilateral anterior uveitis requiring long-term topical steroid treatment and eventually developed bilateral cataracts requiring surgery in both eyes.1
CD4 counts
All our patients had CD4 counts of less than 50 cells/ mm3 at diagnosis of CMVR. In the non-TT group the CD4 count remained at this level until death. In the TT cohort after triple therapy, 6 patients had a CD4 count that remained persistently below 50 cells/mm3. Three patients had a CD4 count boosted beyond 100 cells/mm3, and of these two were above 150 cells/mm3.
Discussion
CMVR is the commonest opportunistic ocular infection in AIDS patients in.the era of Pneumocystis prophylaxis.1 It is also the most substantial cause of visual morbidity in AIDS. This study chronicles the ophthalmic experience of one HIV unit undergoing the transition to triple therapy. We attempt to provide a 'snapshot' of all CMVR patients seen over a 2 year period in the HIV eye clinic. We have seen an increase in patient survival and time to CMVR (2) Note: only affected eyes are shown, Ho, homosexual contact; He, heterosexual contact; B, infected blood products; E, endemic HIV spread; G, intravenous ganciclovir; F, intravenous foscarnet; OG, oral ganciclovir; IG, intravitreal ganciclovir; C, intravenous cidofovir; V, ganciclovir implant (Vitrasert). RD, retinal detachment, aVA loss is the loss of 2 or more lines of Snellen visual acuity, bSurvivor at last follow-up, cVisual loss preceding triple therapy.
relapse and a shift in the pattern of ocular features from zone 1 disease and retinal detachments to that of uveitis and its sequelae. The simultaneous decrease in bilateral disease and zone 1 disease in patients after triple therapy may be related8 and reflects the general improvement in immune function.
Cost of triple therapy
The increased cost of triple therapy appears to be justified by the results reported in a recent multicentre study, which shows substantial health and cost benefits enjoyed by the early adopters of triple therapy as morbidity and mortality have been cut.3 This argues for the extensive use of triple therapy in HIV disease.
Questions raised by widespread use of triple therapy
The questions facing most ophthalmologists managing HIV disease include the visual prognosis with increased survival and implications for the current CMVR screening and treatment protocol.
Increase in inflammatory eye disease and visual prognosis
The rise in the rates of uveitis may be attributed to many causes. 9 has lost 2 lines of best corrected Snellen visual acuity from bilateral cystoid macula oedema, and 2 have a visual acuity of less than 6/60 in the better eye -resulting from old zone 1 disease in 1 patient and from cataracts and inflammatory maculopathy in the other.
Implications for the screening of CMVR
The fall in the incidence of new CMVR is similar to that reported by Jabs et al.,16 who found a decline in the incidence of CMVR in Baltimore by 55% over the past 3 years. CMVR relapses have been considerably reduced since the use of triple therapy, with the median time of progression rising from 79 to 179 days in our TT cohort. The strongest independent risk factor for the development of CMVR previously has been the CD4 count,17 as effective immune response to CMVR is mainly cell-mediated. Triple therapy/highly active anti retroviral therapy (HAART) increases CD4 cell numbers by reducing viral replication. The average CD4 count after triple therapy is 100-150 cells/mm3 (compared with >500 cells/mm3 in non-immunocompromised individuals), resulting in an incomplete immune restitution.18 Under the previous screening regimen, all asymptomatic patients with CD4 counts of less than 50/ mm3 were screened at 3 monthly intervals. The finding of Jacobson et al. 19 was that before triple therapy only 4% of CMVR patients had CD4 counts greater than 50 cells/ mm3, but that after triple therapy 29% had CD4 counts greater than 50 cells/mm3 and 14% had CD4 counts in excess of 100 cells/mm3. The question is whether the CD4 count in the triple therapy era still provides a reliable indicator of the patient's immune function and, if not, what other markers should be used.
Implications for the treatment of CMV and HIV disease
We aim to delay CMVR relapse by an aggressive induction regimen, on which the patient remains on induction dosage of anti-CMV agents until all clinical activity of CMV retinitis is quiescent, rather than the standard 2-3 week induction followed by maintenance treatment. A recent study has shown that this lengthens the time to relapse,zo Recent reports of CMVR remission induced by triple therapyll also raise questions as to the overall management of CMV disease. Patient 22 was noted to have regressed CMVR scars in zone 3 at screening despite no history of previous CMV or treatment. The patient had been on triple therapy since the diagnosis of AIDS. He subsequently had one reactivation of CMVR in that eye, which was successfully treated. A recent study has suggested that in some patients triple therapy alone may boost the immune system sufficiently to avoid the need for anti-CMV maintenance?3 As most anti-CMV regimens are given systemically lifelong, there are potential side-effects of renal impairment and myelosuppression.23 These findings eVidently raise considerations regarding both the cost and patients' quality of life.
Conclusion
It is important that in the era of triple therapy the ophthalmologist is vigilant regarding the new clinical manifestations of HIV eye disease and their implications. The full impact of these new treatment regimens has yet to be assessed.
